Biosputnik
Organization
People
Ceo cso
Sources: reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
R41, Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC), R41HL164196, $300K, 2023–2025, Aug 31, 2023
National Heart, Lung, and Blood Institute
R41, Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis, R41HL156767, $256K, 2021–2023, Apr 9, 2021
Sources: reporter.nih.gov